Dr. du Bois on the Potential Impact of Cytoreductive Surgery in Ovarian Cancer

Andreas du Bois, MD, PhD
Published: Tuesday, Aug 29, 2017



Andreas du Bois, MD, PhD, a professor of gynecologic oncology at Kliniken Essen Mitte, discusses the potential impact of cytoreductive surgery in ovarian cancer.

Surgical resection in recurrent ovarian cancer could add to the prognosis and well-being of the patient, says du Bois.

There are 2 thresholds to pass though, adds du Bois—eligibility for resection and finding the right institution.


Andreas du Bois, MD, PhD, a professor of gynecologic oncology at Kliniken Essen Mitte, discusses the potential impact of cytoreductive surgery in ovarian cancer.

Surgical resection in recurrent ovarian cancer could add to the prognosis and well-being of the patient, says du Bois.

There are 2 thresholds to pass though, adds du Bois—eligibility for resection and finding the right institution.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x